Creo Medical Group Future Growth
Future criteria checks 0/6
Creo Medical Group's revenue is forecast to decline at 4.9% per annum while its annual earnings are expected to grow at 41% per year. EPS is expected to grow by 45.6% per annum. Return on equity is forecast to be -14.7% in 3 years.
Key information
41.0%
Earnings growth rate
45.6%
EPS growth rate
| Medical Equipment earnings growth | 22.3% |
| Revenue growth rate | -4.9% |
| Future return on equity | -14.7% |
| Analyst coverage | Low |
| Last updated | 24 Oct 2024 |
Recent future growth updates
Recent updates
Creo Medical Group PLC (LON:CREO) Screens Well But There Might Be A Catch
Sep 19
Market Cool On Creo Medical Group PLC's (LON:CREO) Revenues Pushing Shares 26% Lower
Mar 02Revenues Tell The Story For Creo Medical Group PLC (LON:CREO) As Its Stock Soars 29%
Dec 29Is Creo Medical Group (LON:CREO) Weighed On By Its Debt Load?
Oct 06Creo Medical (LON:CREO) Is In A Good Position To Deliver On Growth Plans
Feb 03
How Many Creo Medical Limited (LON:CREO) Shares Do Institutions Own?
Dec 09Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 28 | -11 | -14 | -13 | 2 |
| 12/31/2025 | 32 | -11 | -16 | -15 | 3 |
| 12/31/2024 | 34 | -19 | -2 | -16 | 3 |
| 6/30/2024 | 30 | -22 | -22 | -20 | N/A |
| 3/31/2024 | 31 | -22 | -22 | -21 | N/A |
| 12/31/2023 | 31 | -22 | -23 | -22 | N/A |
| 9/30/2023 | 30 | -23 | -24 | -22 | N/A |
| 6/30/2023 | 29 | -25 | -25 | -23 | N/A |
| 3/31/2023 | 28 | -26 | -27 | -24 | N/A |
| 12/31/2022 | 27 | -27 | -28 | -25 | N/A |
| 9/30/2022 | 27 | -28 | -33 | -27 | N/A |
| 6/30/2022 | 26 | -28 | -38 | -30 | N/A |
| 3/31/2022 | 26 | -26 | -35 | -28 | N/A |
| 12/31/2021 | 25 | -25 | -32 | -26 | N/A |
| 9/30/2021 | 24 | -23 | -26 | -22 | N/A |
| 6/30/2021 | 22 | -21 | -19 | -19 | N/A |
| 3/31/2021 | 16 | -21 | -18 | -18 | N/A |
| 12/31/2020 | 9 | -20 | -17 | -16 | N/A |
| 9/30/2020 | 5 | -19 | -17 | -16 | N/A |
| 6/30/2020 | 0 | -17 | -17 | -16 | N/A |
| 3/31/2020 | 0 | -17 | -15 | -14 | N/A |
| 12/31/2019 | 0 | -16 | -13 | -12 | N/A |
| 6/30/2019 | 0 | -13 | -14 | -13 | N/A |
| 3/31/2019 | 0 | -12 | -12 | -11 | N/A |
| 12/31/2018 | N/A | -10 | -10 | -10 | N/A |
| 12/31/2017 | 0 | -8 | N/A | -9 | N/A |
| 9/30/2017 | 0 | -8 | N/A | -8 | N/A |
| 6/30/2017 | N/A | -8 | N/A | -7 | N/A |
| 6/30/2016 | 1 | -5 | N/A | -5 | N/A |
| 2/29/2016 | 1 | -3 | N/A | -3 | N/A |
| 2/28/2015 | N/A | -2 | N/A | -2 | N/A |
| 2/28/2014 | 1 | -2 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CREO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CREO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CREO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CREO's revenue is expected to decline over the next 3 years (-4.9% per year).
High Growth Revenue: CREO's revenue is forecast to decline over the next 3 years (-4.9% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CREO is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 15:50 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Creo Medical Group PLC is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christopher Donnellan | Cavendish |
| Christopher Donnellan | Cavendish Historical (Cenkos Securities) |
| Jyoti Prakash | Edison Investment Research |